PDS Biotechnology Corp (PDSB)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $113.39M
Last updated: Nov 17, 2026 at 4:43 PM ET
PDS Biotechnology Corp (PDSB) Statistics
PDS Biotechnology (PDSB) has a market cap of $113.39M and an enterprise value of $98.15M. Its share count is up 53.48% from a year earlier. Revenue fell 100.00% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 13.44% below the market cap, as cash exceeds debt.
| Market Cap | $113.39M |
|---|---|
| Enterprise Value | $98.15M |
| Latest price (Nov 17, 2026) | $0.89 |
Key Dates
The next earnings report is expected on Mar 29, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 29, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 13, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is up 6.34% over 52 weeks and trades 11.88% below its 50-day average.
| Beta (1Y) | 2.44 |
|---|---|
| 52-Week Change | +6.34% |
| 1-Month Change | -2.48% |
| 3-Month Change | +345.34% |
| 6-Month Change | -10.62% |
| 5-Year Change | -88.04% |
| 10-Year Change | -99.31% |
| Total Return (1Y) | +6.34% |
| Total Return (3Y CAGR) | -47.81% |
| Total Return (5Y CAGR) | -38.47% |
| Max Drawdown (1Y) | -85.97% |
| Max Drawdown (3Y) | -96.95% |
| Sharpe Ratio (1Y) | 0.07 |
| Correlation with SPY (1Y) | 0.19 |
| 50-Day Average | $1.01 |
| 200-Day Average | $0.84 |
| 52-Week Range | $0.20 to $1.79 |
| RSI (14 Days) | 41.5 |
| Average Volume (20 Days) | 5.73M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 3.62x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 3.62x |
|---|---|
| Quick Ratio | 3.62x |
| Debt / Equity | 0.00x |
| Interest Coverage | -3.52x |
Returns and Efficiency
Return on invested capital is -149.78% over the last 12 months, against a 5-year average of -87.00%.
| Return on Equity (ROE) | -239.22% |
|---|---|
| Return on Assets (ROA) | -173.83% |
| Return on Invested Capital (ROIC) | -149.78% |
| Return on Capital Employed (ROCE) | -189.60% |
| ROA (5Y Average) | -69.31% |
| ROIC (5Y Average) | -87.00% |
Scores
PDSB has a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 2 of 9 |
|---|---|
| Piotroski Strength | Weak |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Revenue Growth (YoY) | -100.00% |
| Gross Profit | -$15.13K |
| Operating Income | -$25.59M |
| Pretax Income | -$32.28M |
| Net Income | -$32.28M |
| EBITDA | -$23.79M |
| EBIT | -$25.59M |
| Reported EPS (TTM) | -$0.56 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 72.70% of the $18.57M in total assets.
| Cash and Equivalents | $15.25M |
|---|---|
| Total Debt | $1.09K |
| Net Cash | $15.24M |
| Net Cash Per Share | $0.21 |
| Working Capital | $13.30M |
| Shareholder Equity | $13.50M |
| Book Value Per Share | $0.19 |
| Total Assets | $18.57M |
| Total Liabilities | $5.08M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$19.09M |
|---|---|
| FCF Per Share | -$0.16 |
| Depreciation and Amortization | $1.80M |
Trailing 12 months through Sep 30, 2026.
Growth
| Book Value Per Share Growth (2Y CAGR) | -50.83% |
|---|---|
| Tangible Book Per Share Growth (2Y CAGR) | -50.83% |
Dividends and Yields
PDSB does not pay a dividend.
| Buyback Yield | -40.35% |
|---|---|
| Shareholder Yield | -40.35% |
Stock Splits
The last split was a 1-for-20 reverse split on Mar 18, 2019.
| Last Split Date | Mar 18, 2019 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:20 |
Peer Position
Against 3 similar companies, PDSB has the 3rd highest ROIC.
ROICPeer median -51.32%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -57.30%
| ROIC | -149.78% vs -51.32% median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | -100.00% vs -57.30% median |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About PDSB
What is PDSB's market cap?
PDS Biotechnology has a market cap of $113.39M. Its enterprise value, which adds debt and subtracts cash, is $98.15M.
How many shares of PDSB are outstanding?
PDS Biotechnology has 71.94M shares outstanding. The count is up 53.48% from a year earlier.
Does PDSB pay a dividend?
No. PDS Biotechnology does not pay a dividend.
How much debt does PDSB have?
PDS Biotechnology has $1.09K of total debt and $15.25M of cash and equivalents, a net cash position of $15.24M.
PDSB pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors